Expression and prognostic roles of the G1‐S modulators in hepatocellular carcinoma: p27 independently predicts the recurrence
Expression of cell‐cycle modulators at the G1 ‐S boundary, retinoblastoma gene product (pRb), p21, p16, p27, p53, cyclin D1 , and cyclin E was investigated with 104 hepatocellular carcinomas (HCC), as well as 90 of their adjacent noncancerous lesions and 9 normal liver control specimens. The labelin...
Gespeichert in:
| Veröffentlicht in: | Hepatology (Baltimore, Md.) Md.), 1999-07, Vol.30 (1), p.90-99 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 99 |
|---|---|
| container_issue | 1 |
| container_start_page | 90 |
| container_title | Hepatology (Baltimore, Md.) |
| container_volume | 30 |
| creator | Ito, Yasuhiro Matsuura, Nariaki Sakon, Masato Miyoshi, Eiji Noda, Katsuhisa Takeda, Tsutomu Umeshita, Koji Nagano, Hiroyuki Nakamori, Shoji Dono, Keizo Tsujimoto, Masahiko Nakahara, Masaaki Nakao, Kazuyasu Taniguchi, Naoyuki Monden, Morito |
| description | Expression of cell‐cycle modulators at the G1
‐S boundary, retinoblastoma gene product (pRb), p21, p16, p27, p53, cyclin D1
, and cyclin E was investigated with 104 hepatocellular carcinomas (HCC), as well as 90 of their adjacent noncancerous lesions and 9 normal liver control specimens. The labeling indices (LI) of pRb, p21, p16, and p27 were higher in HCC lesions than in the adjacent noncancerous lesions and normal controls. Especially, p27 LI in noncancerous lesions was significantly higher than that in normal livers (P = .011). Aberrant p53 expression and cyclin D1
and E overexpression were observed exclusively in HCC lesions. pRb was positive in 85.6% of the HCC cases and was not related to any clinicopathological parameters. The p21 LI was generally low (average, 5.5 ± 9.8). Although a negative regulator, p21 LI was higher in cases with intrahepatic metastasis (P = .0359). The p16 LI was significantly decreased (P = .0121) in cases with advanced stage. p27 LI was significantly decreased in cases with portal invasion (P = .0409), poor differentiation (P < .0001), larger size (P = .0421), and intrahepatic metastasis (P = .0878, borderline significance). On the other hand, aberrant p53 expression showed positive relationships with poor differentiation (P
= .0004) and Ki‐67 LI (P = .0047). Cyclin D1
overexpression was found in 32.6% of the cases and occurred more frequently in those with high Ki‐67 LI (P = .0032), pRb expression (P = .0202), poor differentiation (P = .0612, borderline significance), and intrahepatic metastasis (P = .0675, borderline significance). Cyclin E was overexpressed in 35.5% and had positive relationships with Ki‐67 LI (P = .0269) and stage (P = .0125). In univariate analysis, cases with p27 LI < 50 (P = .0004), cyclin D1
overexpression (P = .0041), and cyclin E overexpression (P = .0572, borderline significance) showed poorer outcomes for disease‐free survival (DFS). In multivariate analysis, p27 expression could be recognized as an independent prognostic marker for DFS. These findings suggest that in HCC: 1) p27 is active against HCC progression in early phases and, possibly, hepatocarcinogenesis as a negative regulator and can be a novel prognostic marker for DFS; and 2) cyclin D1
predominantly works for cell‐cycle progression at the G1
‐S boundary |
| doi_str_mv | 10.1002/hep.510300114 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_69854415</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>69854415</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4054-6ce5caa6259f446dc23986365c73073ab79e644a0938a67f941a6569c076196e3</originalsourceid><addsrcrecordid>eNp90Mtu1DAUBmALgejQsmRbeYG6SzmOb3F3VTW0SJVAgq4j1zmhRomd2onaWcEj8Iw8CR5mRFmxsS3r038uhLxhcMoA6nd3OJ1KBhyAMfGMrJisdcW5hOdkBbWGyjBuDsirnL8BgBF185IcFN9IJcSKfF8_Tglz9jFQGzo6pfg1xDx7R1McMNPY0_kO6SX79ePnZzrGbhnsHFOmPtBSu7wdDkP5TNTZ5HyIoz2jU60L6HDCcoR52JRg7Lyb85-0hG5JCYPDI_Kit0PG1_v7kNy8X3-5uKquP15-uDi_rpwAKSrlUDprVS1NL4TqXM1No7iSTnPQ3N5qg2UeC4Y3VuneCGaVVMaBVswo5IfkZJdbBrxfMM_t6PO2cxswLrlVppFCMFlgtYMuxZwT9u2U_GjTpmXQbjfelqnbvxsv_ngfvNyO2P2jdysu4O0e2Ozs0CcbnM9PzkBTN1umd-zBD7j5f9H2av3pqYPfNbmamw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>69854415</pqid></control><display><type>article</type><title>Expression and prognostic roles of the G1‐S modulators in hepatocellular carcinoma: p27 independently predicts the recurrence</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Ito, Yasuhiro ; Matsuura, Nariaki ; Sakon, Masato ; Miyoshi, Eiji ; Noda, Katsuhisa ; Takeda, Tsutomu ; Umeshita, Koji ; Nagano, Hiroyuki ; Nakamori, Shoji ; Dono, Keizo ; Tsujimoto, Masahiko ; Nakahara, Masaaki ; Nakao, Kazuyasu ; Taniguchi, Naoyuki ; Monden, Morito</creator><creatorcontrib>Ito, Yasuhiro ; Matsuura, Nariaki ; Sakon, Masato ; Miyoshi, Eiji ; Noda, Katsuhisa ; Takeda, Tsutomu ; Umeshita, Koji ; Nagano, Hiroyuki ; Nakamori, Shoji ; Dono, Keizo ; Tsujimoto, Masahiko ; Nakahara, Masaaki ; Nakao, Kazuyasu ; Taniguchi, Naoyuki ; Monden, Morito</creatorcontrib><description>Expression of cell‐cycle modulators at the G1
‐S boundary, retinoblastoma gene product (pRb), p21, p16, p27, p53, cyclin D1
, and cyclin E was investigated with 104 hepatocellular carcinomas (HCC), as well as 90 of their adjacent noncancerous lesions and 9 normal liver control specimens. The labeling indices (LI) of pRb, p21, p16, and p27 were higher in HCC lesions than in the adjacent noncancerous lesions and normal controls. Especially, p27 LI in noncancerous lesions was significantly higher than that in normal livers (P = .011). Aberrant p53 expression and cyclin D1
and E overexpression were observed exclusively in HCC lesions. pRb was positive in 85.6% of the HCC cases and was not related to any clinicopathological parameters. The p21 LI was generally low (average, 5.5 ± 9.8). Although a negative regulator, p21 LI was higher in cases with intrahepatic metastasis (P = .0359). The p16 LI was significantly decreased (P = .0121) in cases with advanced stage. p27 LI was significantly decreased in cases with portal invasion (P = .0409), poor differentiation (P < .0001), larger size (P = .0421), and intrahepatic metastasis (P = .0878, borderline significance). On the other hand, aberrant p53 expression showed positive relationships with poor differentiation (P
= .0004) and Ki‐67 LI (P = .0047). Cyclin D1
overexpression was found in 32.6% of the cases and occurred more frequently in those with high Ki‐67 LI (P = .0032), pRb expression (P = .0202), poor differentiation (P = .0612, borderline significance), and intrahepatic metastasis (P = .0675, borderline significance). Cyclin E was overexpressed in 35.5% and had positive relationships with Ki‐67 LI (P = .0269) and stage (P = .0125). In univariate analysis, cases with p27 LI < 50 (P = .0004), cyclin D1
overexpression (P = .0041), and cyclin E overexpression (P = .0572, borderline significance) showed poorer outcomes for disease‐free survival (DFS). In multivariate analysis, p27 expression could be recognized as an independent prognostic marker for DFS. These findings suggest that in HCC: 1) p27 is active against HCC progression in early phases and, possibly, hepatocarcinogenesis as a negative regulator and can be a novel prognostic marker for DFS; and 2) cyclin D1
predominantly works for cell‐cycle progression at the G1
‐S boundary</description><identifier>ISSN: 0270-9139</identifier><identifier>EISSN: 1527-3350</identifier><identifier>DOI: 10.1002/hep.510300114</identifier><identifier>PMID: 10385644</identifier><identifier>CODEN: HPTLD9</identifier><language>eng</language><publisher>Philadelphia, PA: W.B. Saunders</publisher><subject>Adult ; Aged ; Biological and medical sciences ; Carcinoma, Hepatocellular - genetics ; Carcinoma, Hepatocellular - mortality ; Carcinoma, Hepatocellular - pathology ; Carcinoma, Hepatocellular - surgery ; Cell Cycle ; Cell Cycle Proteins ; Cyclin D1 - analysis ; Cyclin E - analysis ; Cyclin-Dependent Kinase Inhibitor p16 - analysis ; Cyclin-Dependent Kinase Inhibitor p21 ; Cyclin-Dependent Kinase Inhibitor p27 ; Cyclins - analysis ; Digestive system ; Female ; Follow-Up Studies ; G1 Phase ; Genes, Retinoblastoma ; Humans ; Investigative techniques, diagnostic techniques (general aspects) ; Liver Neoplasms - genetics ; Liver Neoplasms - mortality ; Liver Neoplasms - pathology ; Liver Neoplasms - surgery ; Male ; Medical sciences ; Microtubule-Associated Proteins - analysis ; Middle Aged ; Neoplasm Staging ; Pathology. Cytology. Biochemistry. Spectrometry. Miscellaneous investigative techniques ; Predictive Value of Tests ; Prognosis ; Recurrence ; Retinoblastoma Protein - analysis ; S Phase ; Survival Analysis ; Time Factors ; Tumor Suppressor Protein p53 - analysis ; Tumor Suppressor Proteins</subject><ispartof>Hepatology (Baltimore, Md.), 1999-07, Vol.30 (1), p.90-99</ispartof><rights>Copyright © 1999 American Association for the Study of Liver Diseases</rights><rights>1999 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4054-6ce5caa6259f446dc23986365c73073ab79e644a0938a67f941a6569c076196e3</citedby><cites>FETCH-LOGICAL-c4054-6ce5caa6259f446dc23986365c73073ab79e644a0938a67f941a6569c076196e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fhep.510300114$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fhep.510300114$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1908284$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10385644$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ito, Yasuhiro</creatorcontrib><creatorcontrib>Matsuura, Nariaki</creatorcontrib><creatorcontrib>Sakon, Masato</creatorcontrib><creatorcontrib>Miyoshi, Eiji</creatorcontrib><creatorcontrib>Noda, Katsuhisa</creatorcontrib><creatorcontrib>Takeda, Tsutomu</creatorcontrib><creatorcontrib>Umeshita, Koji</creatorcontrib><creatorcontrib>Nagano, Hiroyuki</creatorcontrib><creatorcontrib>Nakamori, Shoji</creatorcontrib><creatorcontrib>Dono, Keizo</creatorcontrib><creatorcontrib>Tsujimoto, Masahiko</creatorcontrib><creatorcontrib>Nakahara, Masaaki</creatorcontrib><creatorcontrib>Nakao, Kazuyasu</creatorcontrib><creatorcontrib>Taniguchi, Naoyuki</creatorcontrib><creatorcontrib>Monden, Morito</creatorcontrib><title>Expression and prognostic roles of the G1‐S modulators in hepatocellular carcinoma: p27 independently predicts the recurrence</title><title>Hepatology (Baltimore, Md.)</title><addtitle>Hepatology</addtitle><description>Expression of cell‐cycle modulators at the G1
‐S boundary, retinoblastoma gene product (pRb), p21, p16, p27, p53, cyclin D1
, and cyclin E was investigated with 104 hepatocellular carcinomas (HCC), as well as 90 of their adjacent noncancerous lesions and 9 normal liver control specimens. The labeling indices (LI) of pRb, p21, p16, and p27 were higher in HCC lesions than in the adjacent noncancerous lesions and normal controls. Especially, p27 LI in noncancerous lesions was significantly higher than that in normal livers (P = .011). Aberrant p53 expression and cyclin D1
and E overexpression were observed exclusively in HCC lesions. pRb was positive in 85.6% of the HCC cases and was not related to any clinicopathological parameters. The p21 LI was generally low (average, 5.5 ± 9.8). Although a negative regulator, p21 LI was higher in cases with intrahepatic metastasis (P = .0359). The p16 LI was significantly decreased (P = .0121) in cases with advanced stage. p27 LI was significantly decreased in cases with portal invasion (P = .0409), poor differentiation (P < .0001), larger size (P = .0421), and intrahepatic metastasis (P = .0878, borderline significance). On the other hand, aberrant p53 expression showed positive relationships with poor differentiation (P
= .0004) and Ki‐67 LI (P = .0047). Cyclin D1
overexpression was found in 32.6% of the cases and occurred more frequently in those with high Ki‐67 LI (P = .0032), pRb expression (P = .0202), poor differentiation (P = .0612, borderline significance), and intrahepatic metastasis (P = .0675, borderline significance). Cyclin E was overexpressed in 35.5% and had positive relationships with Ki‐67 LI (P = .0269) and stage (P = .0125). In univariate analysis, cases with p27 LI < 50 (P = .0004), cyclin D1
overexpression (P = .0041), and cyclin E overexpression (P = .0572, borderline significance) showed poorer outcomes for disease‐free survival (DFS). In multivariate analysis, p27 expression could be recognized as an independent prognostic marker for DFS. These findings suggest that in HCC: 1) p27 is active against HCC progression in early phases and, possibly, hepatocarcinogenesis as a negative regulator and can be a novel prognostic marker for DFS; and 2) cyclin D1
predominantly works for cell‐cycle progression at the G1
‐S boundary</description><subject>Adult</subject><subject>Aged</subject><subject>Biological and medical sciences</subject><subject>Carcinoma, Hepatocellular - genetics</subject><subject>Carcinoma, Hepatocellular - mortality</subject><subject>Carcinoma, Hepatocellular - pathology</subject><subject>Carcinoma, Hepatocellular - surgery</subject><subject>Cell Cycle</subject><subject>Cell Cycle Proteins</subject><subject>Cyclin D1 - analysis</subject><subject>Cyclin E - analysis</subject><subject>Cyclin-Dependent Kinase Inhibitor p16 - analysis</subject><subject>Cyclin-Dependent Kinase Inhibitor p21</subject><subject>Cyclin-Dependent Kinase Inhibitor p27</subject><subject>Cyclins - analysis</subject><subject>Digestive system</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>G1 Phase</subject><subject>Genes, Retinoblastoma</subject><subject>Humans</subject><subject>Investigative techniques, diagnostic techniques (general aspects)</subject><subject>Liver Neoplasms - genetics</subject><subject>Liver Neoplasms - mortality</subject><subject>Liver Neoplasms - pathology</subject><subject>Liver Neoplasms - surgery</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Microtubule-Associated Proteins - analysis</subject><subject>Middle Aged</subject><subject>Neoplasm Staging</subject><subject>Pathology. Cytology. Biochemistry. Spectrometry. Miscellaneous investigative techniques</subject><subject>Predictive Value of Tests</subject><subject>Prognosis</subject><subject>Recurrence</subject><subject>Retinoblastoma Protein - analysis</subject><subject>S Phase</subject><subject>Survival Analysis</subject><subject>Time Factors</subject><subject>Tumor Suppressor Protein p53 - analysis</subject><subject>Tumor Suppressor Proteins</subject><issn>0270-9139</issn><issn>1527-3350</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1999</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp90Mtu1DAUBmALgejQsmRbeYG6SzmOb3F3VTW0SJVAgq4j1zmhRomd2onaWcEj8Iw8CR5mRFmxsS3r038uhLxhcMoA6nd3OJ1KBhyAMfGMrJisdcW5hOdkBbWGyjBuDsirnL8BgBF185IcFN9IJcSKfF8_Tglz9jFQGzo6pfg1xDx7R1McMNPY0_kO6SX79ePnZzrGbhnsHFOmPtBSu7wdDkP5TNTZ5HyIoz2jU60L6HDCcoR52JRg7Lyb85-0hG5JCYPDI_Kit0PG1_v7kNy8X3-5uKquP15-uDi_rpwAKSrlUDprVS1NL4TqXM1No7iSTnPQ3N5qg2UeC4Y3VuneCGaVVMaBVswo5IfkZJdbBrxfMM_t6PO2cxswLrlVppFCMFlgtYMuxZwT9u2U_GjTpmXQbjfelqnbvxsv_ngfvNyO2P2jdysu4O0e2Ozs0CcbnM9PzkBTN1umd-zBD7j5f9H2av3pqYPfNbmamw</recordid><startdate>199907</startdate><enddate>199907</enddate><creator>Ito, Yasuhiro</creator><creator>Matsuura, Nariaki</creator><creator>Sakon, Masato</creator><creator>Miyoshi, Eiji</creator><creator>Noda, Katsuhisa</creator><creator>Takeda, Tsutomu</creator><creator>Umeshita, Koji</creator><creator>Nagano, Hiroyuki</creator><creator>Nakamori, Shoji</creator><creator>Dono, Keizo</creator><creator>Tsujimoto, Masahiko</creator><creator>Nakahara, Masaaki</creator><creator>Nakao, Kazuyasu</creator><creator>Taniguchi, Naoyuki</creator><creator>Monden, Morito</creator><general>W.B. Saunders</general><general>Wiley</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>199907</creationdate><title>Expression and prognostic roles of the G1‐S modulators in hepatocellular carcinoma: p27 independently predicts the recurrence</title><author>Ito, Yasuhiro ; Matsuura, Nariaki ; Sakon, Masato ; Miyoshi, Eiji ; Noda, Katsuhisa ; Takeda, Tsutomu ; Umeshita, Koji ; Nagano, Hiroyuki ; Nakamori, Shoji ; Dono, Keizo ; Tsujimoto, Masahiko ; Nakahara, Masaaki ; Nakao, Kazuyasu ; Taniguchi, Naoyuki ; Monden, Morito</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4054-6ce5caa6259f446dc23986365c73073ab79e644a0938a67f941a6569c076196e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1999</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Biological and medical sciences</topic><topic>Carcinoma, Hepatocellular - genetics</topic><topic>Carcinoma, Hepatocellular - mortality</topic><topic>Carcinoma, Hepatocellular - pathology</topic><topic>Carcinoma, Hepatocellular - surgery</topic><topic>Cell Cycle</topic><topic>Cell Cycle Proteins</topic><topic>Cyclin D1 - analysis</topic><topic>Cyclin E - analysis</topic><topic>Cyclin-Dependent Kinase Inhibitor p16 - analysis</topic><topic>Cyclin-Dependent Kinase Inhibitor p21</topic><topic>Cyclin-Dependent Kinase Inhibitor p27</topic><topic>Cyclins - analysis</topic><topic>Digestive system</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>G1 Phase</topic><topic>Genes, Retinoblastoma</topic><topic>Humans</topic><topic>Investigative techniques, diagnostic techniques (general aspects)</topic><topic>Liver Neoplasms - genetics</topic><topic>Liver Neoplasms - mortality</topic><topic>Liver Neoplasms - pathology</topic><topic>Liver Neoplasms - surgery</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Microtubule-Associated Proteins - analysis</topic><topic>Middle Aged</topic><topic>Neoplasm Staging</topic><topic>Pathology. Cytology. Biochemistry. Spectrometry. Miscellaneous investigative techniques</topic><topic>Predictive Value of Tests</topic><topic>Prognosis</topic><topic>Recurrence</topic><topic>Retinoblastoma Protein - analysis</topic><topic>S Phase</topic><topic>Survival Analysis</topic><topic>Time Factors</topic><topic>Tumor Suppressor Protein p53 - analysis</topic><topic>Tumor Suppressor Proteins</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ito, Yasuhiro</creatorcontrib><creatorcontrib>Matsuura, Nariaki</creatorcontrib><creatorcontrib>Sakon, Masato</creatorcontrib><creatorcontrib>Miyoshi, Eiji</creatorcontrib><creatorcontrib>Noda, Katsuhisa</creatorcontrib><creatorcontrib>Takeda, Tsutomu</creatorcontrib><creatorcontrib>Umeshita, Koji</creatorcontrib><creatorcontrib>Nagano, Hiroyuki</creatorcontrib><creatorcontrib>Nakamori, Shoji</creatorcontrib><creatorcontrib>Dono, Keizo</creatorcontrib><creatorcontrib>Tsujimoto, Masahiko</creatorcontrib><creatorcontrib>Nakahara, Masaaki</creatorcontrib><creatorcontrib>Nakao, Kazuyasu</creatorcontrib><creatorcontrib>Taniguchi, Naoyuki</creatorcontrib><creatorcontrib>Monden, Morito</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Hepatology (Baltimore, Md.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ito, Yasuhiro</au><au>Matsuura, Nariaki</au><au>Sakon, Masato</au><au>Miyoshi, Eiji</au><au>Noda, Katsuhisa</au><au>Takeda, Tsutomu</au><au>Umeshita, Koji</au><au>Nagano, Hiroyuki</au><au>Nakamori, Shoji</au><au>Dono, Keizo</au><au>Tsujimoto, Masahiko</au><au>Nakahara, Masaaki</au><au>Nakao, Kazuyasu</au><au>Taniguchi, Naoyuki</au><au>Monden, Morito</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Expression and prognostic roles of the G1‐S modulators in hepatocellular carcinoma: p27 independently predicts the recurrence</atitle><jtitle>Hepatology (Baltimore, Md.)</jtitle><addtitle>Hepatology</addtitle><date>1999-07</date><risdate>1999</risdate><volume>30</volume><issue>1</issue><spage>90</spage><epage>99</epage><pages>90-99</pages><issn>0270-9139</issn><eissn>1527-3350</eissn><coden>HPTLD9</coden><abstract>Expression of cell‐cycle modulators at the G1
‐S boundary, retinoblastoma gene product (pRb), p21, p16, p27, p53, cyclin D1
, and cyclin E was investigated with 104 hepatocellular carcinomas (HCC), as well as 90 of their adjacent noncancerous lesions and 9 normal liver control specimens. The labeling indices (LI) of pRb, p21, p16, and p27 were higher in HCC lesions than in the adjacent noncancerous lesions and normal controls. Especially, p27 LI in noncancerous lesions was significantly higher than that in normal livers (P = .011). Aberrant p53 expression and cyclin D1
and E overexpression were observed exclusively in HCC lesions. pRb was positive in 85.6% of the HCC cases and was not related to any clinicopathological parameters. The p21 LI was generally low (average, 5.5 ± 9.8). Although a negative regulator, p21 LI was higher in cases with intrahepatic metastasis (P = .0359). The p16 LI was significantly decreased (P = .0121) in cases with advanced stage. p27 LI was significantly decreased in cases with portal invasion (P = .0409), poor differentiation (P < .0001), larger size (P = .0421), and intrahepatic metastasis (P = .0878, borderline significance). On the other hand, aberrant p53 expression showed positive relationships with poor differentiation (P
= .0004) and Ki‐67 LI (P = .0047). Cyclin D1
overexpression was found in 32.6% of the cases and occurred more frequently in those with high Ki‐67 LI (P = .0032), pRb expression (P = .0202), poor differentiation (P = .0612, borderline significance), and intrahepatic metastasis (P = .0675, borderline significance). Cyclin E was overexpressed in 35.5% and had positive relationships with Ki‐67 LI (P = .0269) and stage (P = .0125). In univariate analysis, cases with p27 LI < 50 (P = .0004), cyclin D1
overexpression (P = .0041), and cyclin E overexpression (P = .0572, borderline significance) showed poorer outcomes for disease‐free survival (DFS). In multivariate analysis, p27 expression could be recognized as an independent prognostic marker for DFS. These findings suggest that in HCC: 1) p27 is active against HCC progression in early phases and, possibly, hepatocarcinogenesis as a negative regulator and can be a novel prognostic marker for DFS; and 2) cyclin D1
predominantly works for cell‐cycle progression at the G1
‐S boundary</abstract><cop>Philadelphia, PA</cop><pub>W.B. Saunders</pub><pmid>10385644</pmid><doi>10.1002/hep.510300114</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0270-9139 |
| ispartof | Hepatology (Baltimore, Md.), 1999-07, Vol.30 (1), p.90-99 |
| issn | 0270-9139 1527-3350 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_69854415 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete; EZB-FREE-00999 freely available EZB journals |
| subjects | Adult Aged Biological and medical sciences Carcinoma, Hepatocellular - genetics Carcinoma, Hepatocellular - mortality Carcinoma, Hepatocellular - pathology Carcinoma, Hepatocellular - surgery Cell Cycle Cell Cycle Proteins Cyclin D1 - analysis Cyclin E - analysis Cyclin-Dependent Kinase Inhibitor p16 - analysis Cyclin-Dependent Kinase Inhibitor p21 Cyclin-Dependent Kinase Inhibitor p27 Cyclins - analysis Digestive system Female Follow-Up Studies G1 Phase Genes, Retinoblastoma Humans Investigative techniques, diagnostic techniques (general aspects) Liver Neoplasms - genetics Liver Neoplasms - mortality Liver Neoplasms - pathology Liver Neoplasms - surgery Male Medical sciences Microtubule-Associated Proteins - analysis Middle Aged Neoplasm Staging Pathology. Cytology. Biochemistry. Spectrometry. Miscellaneous investigative techniques Predictive Value of Tests Prognosis Recurrence Retinoblastoma Protein - analysis S Phase Survival Analysis Time Factors Tumor Suppressor Protein p53 - analysis Tumor Suppressor Proteins |
| title | Expression and prognostic roles of the G1‐S modulators in hepatocellular carcinoma: p27 independently predicts the recurrence |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T17%3A52%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Expression%20and%20prognostic%20roles%20of%20the%20G1%E2%80%90S%20modulators%20in%20hepatocellular%20carcinoma:%20p27%20independently%20predicts%20the%20recurrence&rft.jtitle=Hepatology%20(Baltimore,%20Md.)&rft.au=Ito,%20Yasuhiro&rft.date=1999-07&rft.volume=30&rft.issue=1&rft.spage=90&rft.epage=99&rft.pages=90-99&rft.issn=0270-9139&rft.eissn=1527-3350&rft.coden=HPTLD9&rft_id=info:doi/10.1002/hep.510300114&rft_dat=%3Cproquest_cross%3E69854415%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=69854415&rft_id=info:pmid/10385644&rfr_iscdi=true |